

# R Michael Tuttle

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2346573/r-michael-tuttle-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

205  
papers

26,401  
citations

60  
h-index

162  
g-index

234  
ext. papers

31,539  
ext. citations

6.3  
avg, IF

6.88  
L-index

#	Paper	IF	Citations
205	Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.. <i>Thyroid</i> , <b>2022</b> ,	6.2	5
204	Nuances in the Surgical Management of Thyroid Cancer.. <i>Indian Journal of Surgical Oncology</i> , <b>2022</b> , 13, 1-6	0.7	
203	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.. <i>Head and Neck</i> , <b>2022</b> ,	4.2	2
202	Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2100714	2.2	4
201	Surgical Management of Low-/Intermediate-Risk Node Negative Thyroid Cancer: A Single-Institution Study Using Propensity Matching Analysis to Compare Thyroid Lobectomy and Total Thyroidectomy. <i>Thyroid</i> , <b>2021</b> ,	6.2	3
200	Invasion of a Recurrent Laryngeal Nerve from Small Well-Differentiated Papillary Thyroid Cancers: Patient Selection Implications for Active Surveillance. <i>Thyroid</i> , <b>2021</b> ,	6.2	4
199	ThyroidEx: Development and Preliminary Validation of a Thyroid Surgery Expectations Measure. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2021</b> , 165, 267-274	5.5	1
198	Prophylactic Lateral Neck Dissection for Medullary Thyroid Carcinoma is not Associated with Improved Survival. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 6572-6579	3.1	6
197	Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment for Low-Risk Differentiated Thyroid Cancer. <i>Endocrine Practice</i> , <b>2021</b> , 27, 383-389	3.2	0
196	Ultrasound-Guided Percutaneous Laser Ablation of the Thyroid Gland in a Swine Model: Comparison of Ablation Parameters and Ablation Zone Dimensions. <i>CardioVascular and Interventional Radiology</i> , <b>2021</b> , 44, 1798-1806	2.7	1
195	A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. <i>Thyroid</i> , <b>2021</b> , 31, 1600-1616	6.2	7
194	Is a Prophylactic Central Compartment Neck Dissection Required in Papillary Thyroid Carcinoma Patients with Clinically Involved Lateral Compartment Lymph Nodes?. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 512-518	3.1	4
193	Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting. <i>Human Pathology</i> , <b>2021</b> , 110, 62-72	3.7	10
192	Perioperative diagnostics of patients referred for radioiodine therapy of differentiated thyroid carcinoma: referral center experience in an iodine-insufficient country. <i>Endocrine</i> , <b>2021</b> , 72, 721-726	4	1
191	Commentary: Re-recurrence after surgical management of recurrent thyroid cancer. <i>Surgery</i> , <b>2021</b> , 169, 844-845	3.6	
190	How Does The AJCC/TNM Staging System Eighth Edition Perform in Thyroid Cancer at A Major Middle Eastern Medical Center?. <i>Endocrine Practice</i> , <b>2021</b> , 27, 607-613	3.2	2
189	Frequent neck US in papillary thyroid cancer likely detects non-actionable findings. <i>Clinical Endocrinology</i> , <b>2021</b> , 94, 504-512	3.4	1

188 Hemithyroidectomy for Differentiated Thyroid Cancer **2021**, 67-80

187 Papillary Carcinoma Observation **2021**, 199-203.e1

186 Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. *Cancer*, **2021**, 127, 4161-4170 6.4 0

185 Does macroscopic extrathyroidal extension to the strap muscles alone affect survival in papillary thyroid carcinoma?. *Surgery*, **2021**, 3.6 2

184 Dynamic Risk Group Analysis and Staging for Differentiated Thyroid Cancer **2021**, 218-224.e1

183 Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Association of Medical Endocrinologists, British Association of Endocrinology and Thyroid Specialists, and the European Association of Endocrinology. *Thyroid*, **2021**, 31, 100-110 4.2 9

182 Assessing the Number of Candidates There Are for Active Surveillance of Low-risk Papillary Thyroid Cancers in the US. *JAMA Otolaryngology - Head and Neck Surgery*, **2020**, 146, 585-586 3.9 5

181 Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies. *Thyroid*, **2020**, 30, 1112-1119 6.2 10

180 Active surveillance for patients with very low-risk thyroid cancer. *Laryngoscope Investigative Otolaryngology*, **2020**, 5, 175-182 2.8 9

179 Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. *Modern Pathology*, **2020**, 33, 1690-1701 9.8 12

178 Dynamic contrast-enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers. *NMR in Biomedicine*, **2020**, 33, e4166 4.4 9

177 Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105, 3777-3783 5.6 43

176 Management of Retropharyngeal Lymph Node Metastases in Differentiated Thyroid Carcinoma. *Thyroid*, **2020**, 30, 688-695 6.2 8

175 Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?. *Surgery*, **2020**, 167, 10-17 3.6 15

174 Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. *Thyroid*, **2020**, 30, 1505-1517 6.2 51

173 How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. *Thyroid*, **2019**, 29, 1792-1803 6.2 15

172 Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 4889-4899 5.6 15

171 Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma. *Annals of Surgical Oncology*, **2019**, 26, 4423-4429 3.1 4

170	Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features. <i>Endocrine</i> , <b>2019</b> , 64, 97-108	4	20
169	Clinical Assessment and Risk Stratification in Differentiated Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2019</b> , 48, 99-108	5.5	8
168	Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> ,	5.6	47
167	Controversies, Consensus, and Collaboration in the Use of I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European	6.2	119
166	ATA HIGH-RISK THYROID CANCER PATIENTS DEMONSTRATING AN EXCELLENT RESPONSE TO THERAPY WITHIN A FEW WEEKS OF INITIAL THERAPY HAVE BETTER THAN EXPECTED CLINICAL OUTCOMES. <i>Endocrine Practice</i> , <b>2019</b> , 25, 287-289	3.2	4
165	Enhanced interdisciplinary communication: development of an interactive thyroid nodule/cancer disease map. <i>Laryngoscope</i> , <b>2019</b> , 129, 269-274	3.6	
164	American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. <i>Head and Neck</i> , <b>2019</b> , 41, 843-856	4.2	7
163	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. <i>Thyroid</i> , <b>2019</b> , 29, 7-26	6.2	59
162	Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 1417-1428	5.6	80
161	Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer. <i>Surgery</i> , <b>2019</b> , 165, 6-11	3.6	30
160	Distinguishing remnant ablation from adjuvant treatment in differentiated thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 7-8	18.1	4
159	Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement. <i>Head and Neck</i> , <b>2018</b> , 40, 663-675	4.2	36
158	A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2018</b> , 13, 77-85	4.1	34
157	Controversial Issues in Thyroid Cancer Management. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 1187-1194	8.9	32
156	No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 620-622	14.6	21
155	Reply: Active Surveillance in Micropapillary Carcinoma. <i>Surgery</i> , <b>2018</b> , 163, 1325-1329	3.6	
154	Treatment decision making in early-stage papillary thyroid cancer. <i>Psycho-Oncology</i> , <b>2018</b> , 27, 61-68	3.9	28
153	Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2018</b> , 68, 55-63	220.7	136

152	Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. <i>Thyroid</i> , <b>2018</b> , 28, 1180-1189	6.2	14
151	Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. <i>Thyroid</i> , <b>2018</b> , 28, 1293-1300	6.2	29
150	Thyroid Cancer Treatment Choice: A Pilot Study of a Tool to Facilitate Conversations with Patients with Papillary Microcarcinomas Considering Treatment Options. <i>Thyroid</i> , <b>2018</b> , 28, 1325-1331	6.2	22
149	Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?. <i>Endocrine</i> , <b>2018</b> , 59, 143-150	4	37
148	Risk Stratification in Differentiated Thyroid Cancer: Importance and Clinical Implications of Preoperative Risk Stratification. <i>VideoEndocrinology</i> , <b>2018</b> , 5,	1.6	1
147	Implementing Key Changes in the American Thyroid Association 2015 Thyroid Nodules/Differentiated Thyroid Cancer Guidelines Across Practice Types. <i>Endocrine Practice</i> , <b>2018</b> , 24, 833-840	3.2	4
146	Risk Stratification and Current Management of Low Risk Thyroid Cancer <b>2018</b> , 111-120		
145	Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. <i>Thyroid</i> , <b>2017</b> , 27, 512-517	6.2	81
144	Patients with Multifocal Macroscopic Papillary Thyroid Carcinoma Have a Low Risk of Recurrence at Early Follow-Up after Total Thyroidectomy and Radioactive Iodine Treatment. <i>European Thyroid Journal</i> , <b>2017</b> , 6, 31-39	4.2	4
143	Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 31, 295-305	6.5	32
142	The "broken chair" in patients with differentiated thyroid cancer. <i>Endocrine</i> , <b>2017</b> , 57, 359-360	4	
141	Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer. <i>Clinical Endocrinology</i> , <b>2017</b> , 87, 566-571	3.4	10
140	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of and as Novel Thyroid Cancer Genes Associated with Tumor Virulence. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5970-5980	12.9	64
139	Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 97, 2226-2237	2.9	4
138	Response to Letter: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2115-2116	5.6	
137	Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. <i>Cancer</i> , <b>2017</b> , 123, 2955-2964	6.4	53
136	Screening for thyroid cancer in survivors of childhood and young adult cancer treated with neck radiation. <i>Journal of Cancer Survivorship</i> , <b>2017</b> , 11, 302-308	5.1	11
135	Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics. <i>Thyroid</i> , <b>2017</b> , 27, 632-640	6.2	44

134	Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2017</b> , 143, 1015-1020	3.9	219
133	Response to Therapy Status Is an Excellent Predictor of Pregnancy-Associated Structural Disease Progression in Patients Previously Treated for Differentiated Thyroid Cancer. <i>Thyroid</i> , <b>2017</b> , 27, 396-401	6.2	17
132	Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 717-722	8.9	55
131	The History of the Follicular Variant of Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 15-22	5.6	73
130	Previous External Beam Radiation Treatment Exposure Does Not Confer Worse Outcome for Patients with Differentiated Thyroid Cancer. <i>Thyroid</i> , <b>2017</b> , 27, 412-417	6.2	4
129	Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine. <i>European Endocrinology</i> , <b>2017</b> , 13, 26-29	3.4	2
128	Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer. <i>Molecular Imaging and Radionuclide Therapy</i> , <b>2017</b> , 26, 80-86	0.8	7
127	Thyroid Differentiated and Anaplastic Carcinoma <b>2017</b> , 881-898		25
126	Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 410-5	3.1	71
125	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , <b>2016</b> , 26, 1-133	6.2	6910
124	Restricting ultrasound thyroid fine needle aspiration biopsy by nodule size: which tumors are we missing? A population-based study. <i>Endocrine</i> , <b>2016</b> , 51, 499-505	4	4
123	Papillary thyroid microcarcinoma and active surveillance - Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 976-977	18.1	2
122	Operative management of locally advanced, differentiated thyroid cancer. <i>Surgery</i> , <b>2016</b> , 160, 738-46	3.6	34
121	Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. <i>Modern Pathology</i> , <b>2016</b> , 29, 985-95	9.8	62
120	Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell-Derived Thyroid Cancer. <i>Thyroid</i> , <b>2016</b> , 26, 518-24	6.2	34
119	An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. <i>Thyroid</i> , <b>2016</b> , 26, 373-80	6.2	122
118	Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes. <i>Thyroid</i> , <b>2016</b> , 26, 219-26	6.2	38
117	Effectiveness of routine ultrasonographic surveillance of patients with low-risk papillary carcinoma of the thyroid. <i>Surgery</i> , <b>2016</b> , 159, 1390-5	3.6	13



116	A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. <i>Thyroid</i> , <b>2016</b> , 26, 144-9	6.2	185
115	Management of advanced medullary thyroid cancer. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 64-71	18.1	75
114	A Risk-adapted Approach to Follow-up in Differentiated Thyroid Cancer. <i>Rambam Maimonides Medical Journal</i> , <b>2016</b> , 7,	1.8	15
113	External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. <i>Head and Neck</i> , <b>2016</b> , 38, 493-8	4.2	46
112	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. <i>JAMA Oncology</i> , <b>2016</b> , 2, 1023-9	13.4	895
111	Changing Trends in the Incidence of Thyroid Cancer in the United States. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2016</b> , 142, 709-11	3.9	124
110	Challenges of Active Surveillance Protocols for Low-Risk Papillary Thyroid Microcarcinoma in the United States. <i>Thyroid</i> , <b>2016</b> , 26, 989-90	6.2	12
109	Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 2692-700	5.6	134
108	Ethical Considerations When Counseling Patients With Thyroid Cancer About Surgery vs Observation. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2016</b> , 142, 406-7	3.9	9
107	Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 933-942	18.1	140
106	Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas. <i>Thyroid</i> , <b>2016</b> , 26, 1588-1597	6.2	34
105	Multi-institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion-weighted MRI. <i>Magnetic Resonance in Medicine</i> , <b>2016</b> , 75, 1708-16	14.4	39
104	Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence. <i>Thyroid</i> , <b>2015</b> , 25, 1235-42	6.2	25
103	Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates. <i>Cancer</i> , <b>2015</b> , 121, 1793-9	6.4	48
102	Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. <i>Human Pathology</i> , <b>2015</b> , 46, 657-64	3.7	103
101	Using diffusion-weighted MRI to predict aggressive histological features in papillary thyroid carcinoma: a novel tool for pre-operative risk stratification in thyroid cancer. <i>Thyroid</i> , <b>2015</b> , 25, 672-80	6.2	27
100	Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary Thyroid Cancer. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 3530-6	3.1	27
99	Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma. <i>Thyroid</i> , <b>2015</b> , 25, 503-8	6.2	22

98	Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on follow-up ultrasound evaluation. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 1561-7	5.6	23
97	Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure. <i>Thyroid</i> , <b>2015</b> , 25, 993-8	6.2	39
96	Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?. <i>Thyroid</i> , <b>2015</b> , 25, 1106-14	6.2	79
95	Response to: Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma". <i>Thyroid</i> , <b>2015</b> , 25, 1269-70	6.2	
94	Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases. <i>Human Pathology</i> , <b>2015</b> , 46, 1789-98	3.7	42
93	Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. <i>Thyroid</i> , <b>2015</b> , 25, 300-7	6.2	94
92	Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. <i>Thyroid</i> , <b>2015</b> , 25, 242-9	6.2	51
91	Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 42-50	2.2	345
90	SERIAL NECK ULTRASOUND IS MORE LIKELY TO IDENTIFY FALSE-POSITIVE ABNORMALITIES THAN CLINICALLY SIGNIFICANT DISEASE IN LOW-RISK PAPILLARY THYROID CANCER PATIENTS. <i>Endocrine Practice</i> , <b>2015</b> , 21, 1372-9	3.2	22
89	Cost-effectiveness analysis of papillary thyroid cancer surveillance. <i>Cancer</i> , <b>2015</b> , 121, 4132-40	6.4	31
88	RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system. <i>Laryngoscope</i> , <b>2015</b> , 125, 2417-24	3.6	19
87	Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare. <i>Thyroid</i> , <b>2015</b> , 25, 865-6	6.2	5
86	Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. <i>Thyroid</i> , <b>2015</b> , 25, 15-27	6.2	79
85	Prognostic factors in papillary microcarcinoma with emphasis on histologic subtyping: a clinicopathologic study of 148 cases. <i>Thyroid</i> , <b>2014</b> , 24, 245-53	6.2	42
84	Comparable outcomes for patients with pT1a and pT1b differentiated thyroid cancer: Is there a need for change in the AJCC classification system?. <i>Surgery</i> , <b>2014</b> , 156, 1484-9; discussion 1489-90	3.6	20
83	Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 1374-8	3.1	31
82	Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases. <i>Thyroid</i> , <b>2014</b> , 24, 1088-95	6.2	37
81	The impact of nodal status on outcome in older patients with papillary thyroid cancer. <i>Surgery</i> , <b>2014</b> , 156, 137-46	3.6	71



80	Update on differentiated thyroid cancer staging. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2014</b> , 43, 401-21	5.5	108
79	Thyroid carcinoma, version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2014</b> , 12, 1671-80; quiz 1680	7.3	113
78	Preoperative neck ultrasound in clinical node-negative differentiated thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3686-93	5.6	13
77	Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1493-501	27.4	605
76	Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. <i>Thyroid</i> , <b>2013</b> , 23, 1401-7	6.2	111
75	American Thyroid Association statement on outpatient thyroidectomy. <i>Thyroid</i> , <b>2013</b> , 23, 1193-202	6.2	181
74	Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging. <i>Oral Oncology</i> , <b>2013</b> , 49, 695-701	4.4	25
73	Prophylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 2285-9	3.1	52
72	Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: a practical approach to clinical decision making. <i>Oral Oncology</i> , <b>2013</b> , 49, 676-83	4.4	29
71	Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm. <i>Journal of Thyroid Research</i> , <b>2013</b> , 2013, 398194	2.6	40
70	A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients. <i>Thyroid</i> , <b>2013</b> , 23, 436-42	6.2	44
69	Recombinant human thyroid-stimulating hormone to stimulate 131-I uptake for remnant ablation and adjuvant therapy. <i>Endocrine Practice</i> , <b>2013</b> , 19, 149-56	3.2	8
68	Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. <i>Clinical Endocrinology</i> , <b>2012</b> , 77, 132-8	3.4	165
67	The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. <i>Thyroid</i> , <b>2012</b> , 22, 1144-52	6.2	499
66	American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. <i>Thyroid</i> , <b>2012</b> , 22, 1104-39	6.2	524
65	Changing trends in well differentiated thyroid carcinoma over eight decades. <i>International Journal of Surgery</i> , <b>2012</b> , 10, 618-23	7.5	29
64	American Thyroid Association statement on the essential elements of interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery. <i>Thyroid</i> , <b>2012</b> , 22, 395-9	6.2	49
63	Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. <i>Thyroid</i> , <b>2012</b> , 22, 877-83	6.2	42

62	American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. <i>Thyroid</i> , <b>2012</b> , 22, 237-44	6.2	156
61	Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer. <i>Indian Journal of Surgical Oncology</i> , <b>2012</b> , 3, 182-9	0.7	5
60	Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. <i>Thyroid</i> , <b>2012</b> , 22, 1007-15	6.2	56
59	Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. <i>Thyroid</i> , <b>2012</b> , 22, 575-84	6.2	95
58	Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. <i>Thyroid</i> , <b>2012</b> , 22, 778-83	6.2	61
57	Similarities and differences in follicular cell-derived thyroid cancer management guidelines used in Europe and the United States. <i>Seminars in Nuclear Medicine</i> , <b>2011</b> , 41, 89-95	5.4	6
56	A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer. <i>Cancer Control</i> , <b>2011</b> , 18, 89-95	2.2	29
55	Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. <i>Clinical Endocrinology</i> , <b>2011</b> , 75, 112-9	3.4	135
54	Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. <i>Cancer</i> , <b>2011</b> , 117, 4439-46	6.4	220
53	Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. <i>Thyroid</i> , <b>2011</b> , 21, 845-53	6.2	94
52	In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. <i>Thyroid</i> , <b>2011</b> , 21, 1317-22	6.2	86
51	An Overview of the Management of Thyroid Cancer <b>2010</b> , 104-116		1
50	Clinical Anatomy, Developmental Aberrations and Endocrinology <b>2010</b> , 181-188		
49	Management of Parathyroid Disease <b>2010</b> , 189-197		
48	Thyroid Imaging <b>2010</b> , 36-44		
47	Pathological Spectrum of Parathyroid Disease <b>2010</b> , 175-180		1
46	Surgical Management of Benign Thyroid Disease <b>2010</b> , 77-86		
45	The Role of Nuclear Medicine <b>2010</b> , 45-54		

44 Thyroid Cytopathology **2010**, 25-35

43 Symptoms, Assessment and Guidelines for Primary Care Referral **2010**, 1-13

42 Endocrine Disorders: Medical Management **2010**, 55-64

41 Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. *Thyroid*, **2010**, 20, 257-63 6.2 53

40 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. *Thyroid*, **2010**, 20, 1341-9 6.2 606

39 The effect of posttherapy <sup>131</sup>I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. *Journal of Nuclear Medicine*, **2010**, 51, 1361-7 8.9 92

38 Oncogenesis and Molecular Targeted Therapy in Thyroid Cancer **2010**, 87-103

37 Symptoms, Differential Diagnosis and Management **2010**, 143-163 0

36 Pathological Spectrum of Thyroid Disease **2010**, 14-24 1

35 Clinical Anatomy and Developmental Aberrations **2010**, 65-76

34 Surgical Management of Thyroid Cancer **2010**, 117-124

33 Medical Management of Thyroid Cancer **2010**, 125-141

32 Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. *Thyroid*, **2009**, 19, 1035-41 6.2 33

31 Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. *Journal of Nuclear Medicine*, **2009**, 50, 1605-10 8.9 82

30 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. *Cancer Research*, **2009**, 69, 4885-93 10.1 403

29 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid*, **2009**, 19, 1167-214 6.2 5121

28 Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). *Thyroid*, **2009**, 19, 119-27 6.2 106

27 Postoperative Management of Well-Differentiated Thyroid Cancer **2009**, 137-148

26	Can risk-adapted treatment recommendations replace the 'one size fits all' approach for early-stage thyroid cancer patients?. <i>Oncology</i> , <b>2009</b> , 23, 592, 600, 603	1.8	2
25	Follow up approaches in thyroid cancer: a risk adapted paradigm. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2008</b> , 37, 419-35, ix-x	5.5	81
24	ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout. <i>Thyroid</i> , <b>2008</b> , 18, 839-46	6.2	22
23	Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. <i>Journal of Nuclear Medicine</i> , <b>2008</b> , 49, 764-70	8.9	125
22	Risk-adapted management of thyroid cancer. <i>Endocrine Practice</i> , <b>2008</b> , 14, 764-74	3.2	63
21	Medical management of thyroid cancer: a risk adapted approach. <i>Journal of Surgical Oncology</i> , <b>2008</b> , 97, 712-6	2.8	50
20	Papillary thyroid cancer: monitoring and therapy. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2007</b> , 36, 753-78, vii	5.5	55
19	Treatment of thyroid cancer: 2007--a basic review. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 69, S92-7	4	14
18	Radioactive iodine therapy in poorly differentiated thyroid cancer. <i>Nature Clinical Practice Oncology</i> , <b>2007</b> , 4, 665-8		15
17	Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors. <i>Thyroid</i> , <b>2007</b> , 17, 543-7	6.2	42
16	Investigational therapies for metastatic thyroid carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2007</b> , 5, 641-6	7.3	14
15	Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. <i>Cancer</i> , <b>2006</b> , 106, 1286-95	6.4	201
14	Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. <i>Cancer</i> , <b>2006</b> , 107, 1255-64	6.4	307
13	Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 498-505	5.6	431
12	Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. <i>Thyroid</i> , <b>2006</b> , 16, 109-42	6.2	1553
11	Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. <i>Journal of Nuclear Medicine</i> , <b>2006</b> , 47, 1587-91	8.9	122
10	Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external-beam irradiation in childhood. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 2281-9	5.6	38
9	Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 6010-6	5.6	63

8	Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 3242-7	5.6	113
7	A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. <i>Journal of Nuclear Medicine</i> , <b>2002</b> , 43, 1482-8	8.9	90
6	Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. <i>Thyroid</i> , <b>2001</b> , 11, 1169-75	6.2	143
5	Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. <i>Modern Pathology</i> , <b>2001</b> , 14, 289-96	9.8	79
4	The Chernobyl accident and its consequences: update at the millennium. <i>Seminars in Nuclear Medicine</i> , <b>2000</b> , 30, 133-40	5.4	62
3	The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 1170-5	5.6	166
2	Differentiated Thyroid Carcinoma That Express Sodium-Iodide Symporter Have a Lower Risk of Recurrence for Children and Adolescents		6
1	The Prognostic Significance of Nodal Metastases from Papillary Thyroid Carcinoma can be Stratified Based on the Size and Number of Metastatic Lymph Nodes, as Well as the Presence of Extranodal Extension ATA Surgical Affairs Committee Taskforce on Thyroid Cancer Nodal Surgery. <i>Thyroid</i> , 120810100637005	6.2	6